Amgen Inc. (AMGN) exhibits 67.2% gross margins and 14.5% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 27.2x enterprise multiple and 6.5% implied options volatility.
Sustained 67.2% gross profitability converts into 24.7% operating margin and 14.5% ROIC, outpacing sector cost of capital.
ROIC: 14.5% // GM: 67.2%YoY revenue trajectory of +10.0% paired with 3.25% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +10.0% // FCF YLD: 3.25%Altman Z-Score of 3.83 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.83 // F-SCORE: 8/9Trading at 32.3x trailing P/E (30.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 32.3x // EV/EBITDA: 27.2xOptions market prices a ±6.5% implied move with a 0.68 put/call ratio around $452.00 max pain.
IMPL MOVE: ±6.5% // P/C: 0.68Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 21.0% net margins.
NET MARGIN: 21.0% // D/E: 5.78x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for AMGN & activate live FRED threshold breach alerts.